NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication11-05-2024
11-05-2024
NEULAND LABORATORIES LTD. - 524558 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate(s)10-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Neuland Laboratories Ltd.
Pharmaceuticals company Neuland Laboratories announced Q4FY24 & FY24 results: FY24 income at Rs 1,571.1 crore, up 30.8% YoY EBITDA at Rs 474.5 crore, up 68.8% YoY Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We surpassed revenues of Rs 1,500 crore in FY24 with EBITDA at over 30%. This has been driven by high growth in the CMS business and steady growth of the Specialty GDS business, both of which were in line with our plans and expectations. Another key element is the work on optimizing costs & processes which will also make us truly sustainable.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw robust growth in FY24 as some projects are near launch while key commercial products continue to scale. Our growing reputation and the macro-environment are ensuring that exciting opportunities come our way even as we work towards building a further differentiated customer experience. We will continue to invest for the future by adding capacity and capabilities.” Result PDF10-05-2024
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investors Presentation on the Financial Results of the Company for the quarter and year ended March 31, 202410-05-2024
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial results for the quarter and year ended March 31, 202410-05-2024
NEULAND LABORATORIES LTD. - 524558 - Re-Appointment Of Statutory Auditors
Re-appointment of Statutory Auditors10-05-2024
NEULAND LABORATORIES LTD. - 524558 - Book Closure For Dividend And Annual General Meeting Scheduled On Wednesday, July 31, 2024
Book closure for dividend and Annual General Meeting scheduled on Wednesday, July 31, 202410-05-2024
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Dividend Updates
Recommendation of final dividend for the financial year 2023-2410-05-2024
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Outcome for Recommendation Of Final Dividend For The Financial Year 2023-24
Recommendation of final dividend for the financial year 2023-2410-05-2024
NEULAND LABORATORIES LTD. - 524558 - Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2023-2024
Audited Financial Results and recommendation of final dividend for financial year 2023-202410-05-2024